{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:40:20Z","timestamp":1786718420244,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/0973-1482.184514","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"742","source":"Crossref","is-referenced-by-count":6,"title":["Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen"],"prefix":"10.4103","volume":"14","author":[{"given":"Yakup","family":"Bozkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6kmenUmut","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NuriyeYildirim","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Hocazade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NebiSerkan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurullah","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.184514-1","first-page":"3493","volume-title":"Prognostic significance of signet ring gastric cancer","author":"Taghavi","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.184514-2","first-page":"878","volume-title":"Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation","author":"Piessen","year":"2009","journal-title":"Ann Surg"},{"key":"key-10.4103\/0973-1482.184514-3","first-page":"5692","volume-title":"Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer","author":"Zu","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"key-10.4103\/0973-1482.184514-4","unstructured":"Lauwers G, Carneiro F, Graham D, Curado M, Franceschi S. Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010. p. 48-58."},{"key":"key-10.4103\/0973-1482.184514-5","first-page":"31","volume-title":"The two h\u0131stolog\u0131cal ma\u0131n types of gastr\u0131c carc\u0131noma: D\u0131ffuse and so-called intest\u0131nal-type carc\u0131noma.An attempt at a histo-cl\u0131n\u0131cal class\u0131f\u0131cat\u0131on","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"key-10.4103\/0973-1482.184514-6","first-page":"2475","volume-title":"Gastric carcinoma.A pathobiological classification","author":"Ming","year":"1977","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.184514-7","first-page":"251","volume-title":"Carcinoma of the stomach in incipient phase: Its histogenesis and histological appearances","author":"Nakamura","year":"1968","journal-title":"Gan"},{"key":"key-10.4103\/0973-1482.184514-8","first-page":"11428","volume-title":"Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge","author":"Pernot","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0973-1482.184514-9","first-page":"4991","volume-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group","author":"Van","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.184514-10","first-page":"403","volume-title":"Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)","author":"Keskin","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"key-10.4103\/0973-1482.184514-11","first-page":"680","volume-title":"The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma","author":"Ozdemir","year":"2010","journal-title":"Med Oncol"},{"key":"key-10.4103\/0973-1482.184514-12","first-page":"2997","volume-title":"Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma","author":"Chi","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"key-10.4103\/0973-1482.184514-13","first-page":"700","volume-title":"Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: Results from a Chinese mono-institutional study","author":"Jiang","year":"2011","journal-title":"J Surg Oncol"},{"key":"key-10.4103\/0973-1482.184514-14","first-page":"43","volume-title":"Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach","author":"Kwon","year":"2014","journal-title":"Gastric Cancer"},{"key":"key-10.4103\/0973-1482.184514-15","first-page":"64","volume-title":"Advanced gastric carcinoma with signet ring cell histology","author":"Li","year":"2007","journal-title":"Oncology"},{"key":"key-10.4103\/0973-1482.184514-16","first-page":"221","volume-title":"Prognostic significance of signet ring cell carcinoma of the stomach","author":"Kim","year":"1994","journal-title":"Surg Oncol"},{"key":"key-10.4103\/0973-1482.184514-17","first-page":"341","volume-title":"Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Safety and efficacy in a multicenter cohort","author":"Pernot","year":"2014","journal-title":"Gastric Cancer"},{"key":"key-10.4103\/0973-1482.184514-18","doi-asserted-by":"crossref","unstructured":"Pernot S, Dubreuil O, Tougeron D, Soudan D, Bachet JB, Lep\u00e8re C, et al. Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and\/or poorly differentiated gastric adenocarcinoma: A retrospective study of AGEO. In: ASCO Annual Meeting Proceedings. 2015. p. e15048.","DOI":"10.1200\/jco.2015.33.15_suppl.e15048"},{"key":"key-10.4103\/0973-1482.184514-19","first-page":"1678","volume-title":"Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma","author":"Bamboat","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"key-10.4103\/0973-1482.184514-20","first-page":"319","volume-title":"Estrogen receptor beta is expressed in human stomach adenocarcinoma","author":"Matsuyama","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"key-10.4103\/0973-1482.184514-21","first-page":"1470","volume-title":"Clinicopathological and prognostic features of hepatoid adenocarcinoma of the stomach","author":"Zhang","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"key-10.4103\/0973-1482.184514-22","first-page":"601","volume-title":"Clinicopathologic features of gastric carcinoma with signet ring cell histology","author":"Zhang","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"key-10.4103\/0973-1482.184514-23","first-page":"1418","volume-title":"Pathology and prognosis of gastric carcinoma: Well versus poorly differentiated type","author":"Adachi","year":"2000","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.184514-24","first-page":"913","volume-title":"Helical hydro-CT for diagnosis and staging of gastric carcinoma","author":"D\u00fcx","year":"1999","journal-title":"J Comput Assist Tomogr"},{"key":"key-10.4103\/0973-1482.184514-25","first-page":"508","volume-title":"Indication for endoscopic mucosal resection in early signet ring cell gastric cancer","author":"Ha","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"key-10.4103\/0973-1482.184514-26","first-page":"234","volume-title":"Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer","author":"Wang","year":"2016","journal-title":"Gastric Cancer"},{"key":"key-10.4103\/0973-1482.184514-27","first-page":"230","volume-title":"Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer","author":"Kos","year":"2011","journal-title":"Chemotherapy"},{"key":"key-10.4103\/0973-1482.184514-28","first-page":"233","volume-title":"Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: A retrospective analysis of single institution","author":"Inal","year":"2012","journal-title":"Neoplasma"},{"key":"key-10.4103\/0973-1482.184514-29","first-page":"81","volume-title":"Review of second-line chemotherapy for advanced gastric adenocarcinoma","author":"Wilson","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key-10.4103\/0973-1482.184514-30","first-page":"886","volume-title":"Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma","author":"Lee","year":"2007","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.184514-31","first-page":"5195","volume-title":"Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer","author":"Reiter","year":"2000","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0973-1482.184514-32","first-page":"1075","volume-title":"Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer","author":"Ucar","year":"2008","journal-title":"Adv Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:34:57Z","timestamp":1786714497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0973-1482.184514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"alternative-id":["184514"],"URL":"https:\/\/doi.org\/10.4103\/0973-1482.184514","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}